SCHEMBL17169392

SCHEMBL17169392

CCCC(=O)c1c(O)c2ccccc2oc1=O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.86
HTT P42858 3/20 0.86
CA12 O43570 1/20 0.68
CA9 Q16790 1/20 0.68
ALDH1A1 P00352 6/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
TP53 P04637 2/20 0.66
TSHR P16473 2/20 0.66
MAPK1 P28482 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
KDM4E B2RXH2 5/20 0.64
MAPT P10636 3/20 0.64
HPGD P15428 3/20 0.64
GAA P10253 2/20 0.64
ALOX15 P16050 2/20 0.64
KMT2A Q03164 2/20 0.64
HSD17B10 Q99714 1/20 0.64
RECQL P46063 1/20 0.62
POLB P06746 1/20 0.61
NPC1 O15118 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29155366 0.84 CA12 (0.70) LMNAHTTCA12CA9ALDH1A1
SCHEMBL7949780 0.82 LMNA (0.64) LMNAHTTCA12CA9ALDH1A1
SCHEMBL30933370 0.81 CA12 (1.00) LMNAHTTCA12CA9ALDH1A1
SCHEMBL3527681 0.81 CA12 (1.00) LMNAHTTCA12CA9ALDH1A1
SCHEMBL11376226 0.81 LMNA (0.63) LMNAHTTCA12CA9ALDH1A1
SCHEMBL17022461 0.81 LMNA (0.70) LMNAHTTCA12CA9ALDH1A1
SCHEMBL17022559 0.80 LMNA (0.69) LMNAHTTCA12CA9ALDH1A1
SCHEMBL8312814 0.80 LMNA (0.62) LMNAHTTCA12CA9ALDH1A1
SCHEMBL17022685 0.80 LMNA (0.68) LMNAHTTCA12CA9ALDH1A1
SCHEMBL17022521 0.80 LMNA (0.68) LMNAHTTCA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512075-B2 Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug OKAYAMA UNIVERSITY (JP) 2016-12-06 US disclosed
US-20150291523-A1 COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2015-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291523-A1 COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG FURIN, ACE, SHARPIN LMNA 1262/4885HTT 366/4885CA12 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.